Fibrosis markers and CRIM1 increase in chronic heart failure of increasing severity

References

• Antoniou KM, Soufla G, Lymbouridou R, et al. (2010). Expression analysis of angiogenic growth factors and biological axis CXCL12/CXCR4 axis in idiopathic pulmonary fibrosis. Connect Tissue Res 51:71–80
   PubMed Web of Science ®Google Scholar
• Aukrust P, Ueland T, Lien E, et al. (1999). Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 83:376–82
   PubMed Web of Science ®Google Scholar
• Barasch E, Gottdiener JS, Aurigemma G, et al. (2009). Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study. Circ Heart Fail 2:303–10
   PubMed Web of Science ®Google Scholar
• Brilla CG, Funck RC, Rupp H. (2000). Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102:1388–93
   PubMed Web of Science ®Google Scholar
• Ciulla M, Paliotti R, Hess DB, et al. (1997). Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr 10:657–64
   PubMed Web of Science ®Google Scholar
• Debl K, Djavidani B, Buchner S, et al. (2006). Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis. Heart 92:1447–51
   PubMedGoogle Scholar
• de Vega S, Iwamoto T, Yamada Y. (2009). Fibulins: multiple roles in matrix structures and tissue functions. Cell Mol Life Sci 66:1890–902
   PubMed Web of Science ®Google Scholar
• Dixon DL, Griggs KM, Bersten AD, De Pasquale CG. (2011). Systemic inflammation and cell activation reflects morbidity in chronic heart failure. Cytokine 56:593–9
   PubMedGoogle Scholar
• Eleuteri E, Mezzani A, Di Stefano A, et al. (2013). Aerobic training and angiogenesis activation in patients with stable chronic heart failure: a preliminary report. Biomarkers 18:418–24
   PubMed Web of Science ®Google Scholar
• Farris AB, Colvin RB. (2012). Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens 21:289–300
   PubMed Web of Science ®Google Scholar
• Fassbach M, Schwartzkopff B. (2005). Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Kardiol 94:328–35
   PubMedGoogle Scholar
• Giannuzzi P, Imparato A, Temporelli PL, et al. (1994). Doppler-derived mitral deceleration time of early filling as a strong predictor of pulmonary capillary wedge pressure in postinfarction patients with left ventricular systolic dysfunction. J Am Coll Cardiol 23:1630–7
   PubMed Web of Science ®Google Scholar
• Glienke J, Sturz A, Menrad A, Thierauch KH. (2002). CRIM1 is involved in endothelial cell capillary formation in vitro and is expressed in blood vessels in vivo. Mech Dev 119:165–75
   PubMed Web of Science ®Google Scholar
• Grgurevic L, Macek B, Healy DR, et al. (2011). Circulating bone morphogenetic protein 1-3 isoform increases renal fibrosis. J Am Soc Nephrol 22:681–92
   PubMed Web of Science ®Google Scholar
• Harris KM, Spirito P, Maron MS, et al. (2006). Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 114:216–25
   PubMedGoogle Scholar
• Heinke J, Wehofsits L, Zhou Q, et al. (2008). BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis. Circ Res 103:804–12
   PubMedGoogle Scholar
• House SL, House BE, Glascock B, et al. (2010). Fibroblast growth factor 2 mediates isoproterenol-induced cardiac hypertrophy through activation of the extracellular regulated kinase. Mol Cell Pharmacol 2:143–54
   PubMedGoogle Scholar
• Izawa H, Murohara T, Nagata K, et al. (2005). Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 112:2940–5
   PubMed Web of Science ®Google Scholar
• Jaffe M, Sesti C, Washington IM, et al. (2012). Transforming growth factor-β signaling in myogenic cells regulates vascular morphogenesis, differentiation, and matrix synthesis. Arterioscler Thromb Vasc Biol 32:e1–11
   PubMedGoogle Scholar
• Leone AM, Rutella S, Bonanno G, et al. (2006). Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction. Int J Cardiol 111:202–8
   PubMed Web of Science ®Google Scholar
• López B, González A, Varo N, et al. (2001). Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 38:1222–6
   PubMed Web of Science ®Google Scholar
• Luo DD, Phillips A, Fraser D. (2010). Bone morphogenetic protein-7 inhibits proximal tubular epithelial cell Smad3 signaling via increased SnoN expression. Am J Pathol 176:1139–47
   PubMed Web of Science ®Google Scholar
• McLenachan JM, Dargie HJ. (1990). Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens 3:735–40
   PubMed Web of Science ®Google Scholar
• Moon JC, Mogensen J, Elliott PM, et al. (2005). Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart 91:1036–40
   PubMedGoogle Scholar
• Moon JC, Sachdev B, Elkington AG, et al. (2003). Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24:2151–5
   PubMed Web of Science ®Google Scholar
• Moser M, Yu Q, Bode C, et al. (2007). BMPER is a conserved regulator of hematopoietic and vascular development in zebrafish. J Mol Cell Cardiol 43:243–53
   PubMedGoogle Scholar
• Myllärniemi M, Lindholm P, Ryynänen MJ, et al. (2008). Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am J Respir Crit Care Med 177:321–9
   PubMed Web of Science ®Google Scholar
• Olivetti G, Melissari M, Balbi T, et al. (1994). Myocyte cellular hypertrophy is responsible for ventricular remodelling in the hypertrophied heart of middle aged individuals in the absence of cardiac failure. Cardiovasc Res 28:1199–208
   PubMedGoogle Scholar
• Onichtchouk D, Chen YG, Dosch R, et al. (1999). Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature 401:480–5
   PubMed Web of Science ®Google Scholar
• Pegorier S, Campbell GA, Kay AB, Lloyd CM. (2010). Bone morphogenetic protein (BMP)-4 and BMP-7 regulate differentially transforming growth factor (TGF)-beta1 in normal human lung fibroblasts (NHLF). Respir Res 11:85–96
   PubMed Web of Science ®Google Scholar
• Querejeta R, López B, González A, et al. (2004). Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 110:1263–8
   PubMed Web of Science ®Google Scholar
• Rose RA, Jiang H, Wang X, et al. (2008). Bone marrow-derived mesenchymal stromal cells express cardiac-specific markers, retain the stromal phenotype, and do not become functional cardiomyocytes in vitro. Stem Cells 26:2884–92
   PubMed Web of Science ®Google Scholar
• Rossi MA. (1998). Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 16:1031–41
   PubMed Web of Science ®Google Scholar
• Schwartzkopff B, Brehm M, Mundhenke M, Strauer BE. (2000). Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 36:220–5
   PubMed Web of Science ®Google Scholar
• Sekiya T, Oda T, Matsuura K, Akiyama T. (2004). Transcriptional regulation of the TGF-beta pseudoreceptor BAMBI by TGF-beta signaling. Biochem Biophys Res Commun 320:680–4
   PubMed Web of Science ®Google Scholar
• Tanaka M, Fujiwara H, Onodera T, et al. (1986). Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 55:575–81
   PubMedGoogle Scholar
• Wang S, Sun A, Li L, et al. (2012). Up-regulation of BMP-2 antagonizes TGF-β1/ROCK-enhanced cardiac fibrotic signalling through activation of Smurf1/Smad6 complex. J Cell Mol Med 16:2301–10
   PubMed Web of Science ®Google Scholar
• Wasserman K, Hansen JE, Sue DY, et al., eds. (2005). Principles of exercise testing and interpretation including pathophysiology and clinical applications. 4th ed. Philadelphia (PA): Lippincott Williams &Wilkins
   Google Scholar
• Weber KT. (2000). Fibrosis and hypertensive heart disease. Curr Opin Cardiol 15:264–72
   PubMed Web of Science ®Google Scholar
• Weidemann F, Breunig F, Beer M, et al. (2005). The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26:1221–7
   PubMed Web of Science ®Google Scholar
• Wilkinson L, Kolle G, Wen D, et al. (2003). CRIM1 regulates the rate of processing and delivery of bone morphogenetic proteins to the cell surface. J Biol Chem 278:34181–8
   PubMed Web of Science ®Google Scholar
• Xavier S, Gilbert V, Rastaldi MP, et al. (2010). BAMBI is expressed in endothelial cells and is regulated by lysosomal/autolysosomal degradation. PLoS One 5:e12995
   PubMed Web of Science ®Google Scholar
• Yanagisawa H, Davis EC. (2010). Unraveling the mechanism of elastic fiber assembly: the roles of short fibulins. Int J Biochem Cell Biol 42:1084–93
   PubMed Web of Science ®Google Scholar
• Yang T, Chen SL, Lu XJ, et al. (2012). Bone morphogenetic protein 7 suppresses the progression of hepatic fibrosis and regulates the expression of gremlin and transforming growth factor β1. Mol Med Rep 6:246–52
   PubMed Web of Science ®Google Scholar
• Yang YL, Ju HZ, Liu SF, et al. (2011). BMP-2 suppresses renal interstitial fibrosis by regulating epithelial-mesenchymal transition. J Cell Biochem 112:2558–65
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Hanai J, Sugimoto H, et al. (2003). BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9:964–8
   PubMed Web of Science ®Google Scholar
• Zhao T, Zhao W, Chen Y, et al. (2011). Acidic and basic fibroblast growth factors involved in cardiac angiogenesis following infarction. Int J Cardiol 152:307–13
   PubMedGoogle Scholar